Northwest Biotherapeutics has completed the acquisition of Advent BioServices Ltd., making Advent a wholly owned subsidiary. The company expects the integration to enable efficiencies and scale-up of operations, including streamlining supply chain and facilities management, reallocating resources from the London GMP facility to the Sawston, UK facility and U.S. capacity, and facilitating manufacturing scale-up. As part of the transaction, 19 million previously issued NWBio securities are reverting back to the company, and NWBio is acquiring all of Advent's fixed assets, intellectual property, and other intangibles. The payment for the acquisition will be made in installments over two years, with potential acceleration after regulatory approval of DCVax-L, and includes £1.4 million and net accounts payable due for prior contract services.